News Assay Able to Detect Neuron Damage in Blood May Serve as Early MS Diagnostic Tool Assay Able to Detect Neuron Damage in Blood May Serve as Early MS Diagnostic Tool by Patricia Silva, PhD | November 17, 2016 Share this article: Share article via email Copy article link Quanterix and UmanDiagnosticsĀ are workingĀ to advanceĀ an assay capable of detecting neuron damage in a blood sample ā a tool that could aid in the earlyĀ diagnosis of multiple sclerosis (MS) and other neurodegenerative conditions. The collaboration brings Quanterixā Simoa technology together with Umanās antibodies against neurofilament light (Nf-L) ā a marker of nerve cell degeneration. In early disease stages, the factor is found in extremely low concentrations in the blood, a reason it hasn’t been usedĀ until now. The assay is ultrasensitive, Quanterix reported, and able to get around that problem. Simoa is a digital immunoassay that can quantify a range of different molecules related to neurodegeneration. Together with Uman’s antibodies, the Simoa Nf-L assay is reported to be sufficiently sensitive toĀ detect Nf-L, a neuronal breakdown product, in the serum, plasma, and cerebrospinal fluid. The assay can be applied in both the clinical and the research setting, as the antibodies can also detect mouse, bovine and macaque versions of Nf-L. “We are extremely pleased to be working closely with Quanterix to provide Uman’s highly specific Nf-L antibodies for use in the Simoa assay format. This enables the worldās most specific and sensitive assay for Nf-L,ā Dr. Niklas Norgren, CEO of UmanDiagnostics, said in a press release. āThe Simoa Nf-L assay is capable of detecting this highly informative neuronal damage biomarker directly in blood, enabling simplified assessment of a variety of neurological disorders, such as Alzheimer’s, Parkinson’s, Multiple Sclerosis,” Norgren added, “and potentially a critical way to access concussion-related neurological issues.” Quanterix also announced that researchers Ā from the University of Mississippi Medical Center and the German Center for Neurodegenerative DiseaseĀ recently presented dataĀ on Quanterixā Simoa technology at the recentĀ Society for Neuroscience 2016 Annual Meeting in San Diego. āThis yearās Neuroscience event is a great opportunity for researchers to showcase groundbreaking discoveries,ā said Kevin Hrusovsky, CEO and executive chairman of Quanterix.Ā āOur collaboration with UmanDiagnostics will provide critical, commercial availability of our Simoa-based assay, which can detect and quantify Nf-L in blood. We look forward to advancing research with this sensitive assay and uncovering groundbreaking discoveries in neurology disease.ā Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags diagnosis, neurofilament light, Quanterix
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada
April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients